Inhibrx Biosciences, Inc. INBX
Regular-session close
After hours · Nov 19, 4:01 PM ET
- YTD
- -5.91%
- 1 year
- -9.51%
5D -10.12 (-11.98%)
- Market cap
- 1.10B
- Revenue (ttm)
- 2.00M
- EPS (ttm)
- -9.06
- Shares out
- 14.77M
- Forward P/E
- -8.71
- YTD return
- -5.91%
- 1-year return
- -9.51%
- 50-day average
- 92.72
- 200-day average
- 92.58
- Enterprise value
- 1.10B
- Volume
- 420.89K
- Avg volume
- 304.38K
- Open
- 70.19
- Previous close
- 69.06
- Day's range
- 69.49 – 80.65
- 52-week range
- 57.30 – 155.29
- Beta
- 4.04
- Analysts
- Strong Buy
- Price target
- 258.33 (+247.5%)
- Earnings date
- Mar 18, 2027
Key statistics
- Price / sales
- 548.89
- Free cash flow
- -81.11M
- Total cash
- 199.47M
- Total debt
- 281.44M
- Short % of float
- 30.63%
Fundamental scorecard
4 of 25 checks passed on INBX’s reported financials
4of 25 checks passed
- Value 1 of 5
- Growth 2 of 5
- Profitability 0 of 5
- Financial health 1 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 220.00
- Target (mean)
- 258.33
- Target (high)
- 325.00
- Strong buy0
- Buy3
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 18, 2027
Expected Mar 18, 2027. Consensus EPS estimate -2.36.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 18, 2027 | Dec 30, 2026 | -2.57 | — | — | — |
| Nov 13, 2026 | Sep 30, 2026 | -2.45 | -2.46 | -0.01 | -0.41% |
| Aug 13, 2026 | Jun 30, 2026 | -2.28 | -2.34 | -0.06 | -2.63% |
| May 14, 2026 | Mar 31, 2026 | -2.37 | -2.15 | +0.22 | +9.28% |
| Mar 19, 2026 | Dec 31, 2025 | -2.08 | -2.11 | -0.03 | -1.44% |
| Nov 14, 2025 | Sep 30, 2025 | -2.08 | -2.28 | -0.20 | -9.62% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 16, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 24, 2026 | HC Wainwright & Co. | init | — | Buy |
| Apr 8, 2026 | Stifel | init | — | Buy |
| Aug 22, 2025 | JMP Securities | reit | Market Perform | Market Perform |
| May 15, 2025 | JMP Securities | reit | Market Perform | Market Perform |
| Mar 18, 2025 | Citizens Capital Markets | reit | Market Perform | Market Perform |
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- inhibrx.com
News
Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma
Inhibrx Biosciences Analyst Cuts Price Target Despite Data Catalysts In 2027 HC Wainwright & Co. Maintains Buy on Inhibrx Biosciences, Lowers Price Target to $220
Inhibrx Reports Third Quarter 2026 Financial Results
12 Health Care Stocks Moving In Wednesday's Intraday Session
Inhibrx Biosciences (NASDAQ:INBX) Shares Cross Below 200-Day Moving Average – Here’s What Happened
Inhibrx Announces Participation in Upcoming Scientific Conferences
Connect Biopharma (NASDAQ:CNTB) & Inhibrx Biosciences (NASDAQ:INBX) Critical Contrast
Inhibrx's Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
Inhibrx Biosciences (NASDAQ:INBX) Shares Climb 3.7% on Insider Buying Activity
Your note
Sign in to keep a note on INBX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FORSYTH DOUGLAS | Director | Purchase | Sep 7, 2026 | 0 |
| KAYYEM JON FAIZ | Director | Purchase | Sep 22, 2026 | 0 |
| LAPPE MARK | Chief Executive Officer | Purchase | Oct 13, 2026 | 0 |
| MANHARD KIMBERLY J | Director | Sale | Sep 14, 2026 | 0 |
| VIKING GLOBAL INVESTORS LP | Beneficial Owner of more than 10% of a Class of Security | Sale | Oct 6, 2025 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Morgan Stanley | 8.94% | 1,320,661 | 98.16M | Sep 29, 2026 |
| Perceptive Advisors Llc | 8.75% | 1,292,463 | 96.07M | Sep 29, 2026 |
| Sanofi | 7.84% | 1,157,926 | 86.07M | Sep 29, 2026 |
| Viking Global Investors, L.P. | 7.50% | 1,108,008 | 82.36M | Sep 29, 2026 |
| HighTower Advisors, LLC | 5.99% | 884,441 | 65.74M | Sep 29, 2026 |
| Schonfeld Strategic Advisors Llc | 5.60% | 827,280 | 61.49M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.50% | 369,641 | 27.48M | Jun 29, 2026 |
| SmallCap World Fund Inc | 2.39% | 353,292 | 26.26M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.20% | 324,794 | 24.14M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.68% | 247,839 | 18.42M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.74% | 109,883 | 8.17M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.70% | 103,938 | 7.73M | Aug 30, 2026 |
